Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

By K. Chung, J. Shia, N. Kemeny, M. Shah, G. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, Lawrence H. Schwartz and 4 more. Journal of Clinical Oncology, 2005

1,142 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0ae58fddbb80f171e4271cf130551ad755d3bc94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Ping Wee
2. Zhixiang Wang

Citations in the corpus

• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (2006, background): “Recently, a 25% objective response rate was obtained in a series of colorectal cancers that did not express EGFR by immunohistochemistry (4), highlighting the potential existence of other predictive markers of response to cetuximab.”
• Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “For example, increased EGFR expression, typically determined by immunohistochemistry, was shown to not correlate with response to EGFR inhibitors [381,382], whereas another studied showed a positive correlation [383].”